Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Tomandlova, Marie ^a   Jarkovsky, Jiri ^a   Tomandl, Josef ^a   Kubkova, Lenka ^a,b,c   Kala, Petr ^a,c   Littnerova, Simona ^a   Gottwaldova, Jana ^a,c   Kubena, Petr ^a,c   Ganovska, Eva ^a,c   Poloczek, Martin ^a,c   Spinar, Jindrich ^a,b,c   Mueller, Christian ^d   Mebazaa, Alexandre ^e   Pavkova Goldbergova, Monika ^a   Parenica, Jiri ^a,b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; NEOPTERIN; NITRATE; NITRITE; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA; 8-OXO-7-HYDRODEOXYGUANOSINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DEOXYGUANOSINE; SERUM AMYLOID P; TROPONIN I; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANALOGS AND DERIVATIVES; BLOOD; EVALUATION STUDY; HEART INFARCTION; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; DEOXYGUANOSINE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NEOPTERIN; NITRITES; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; SERUM AMYLOID P-COMPONENT; TROPONIN I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928244007     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/159051     Document Type: Article

References (42)

1. C. Mueller, H. J. Buettner, J. M. Hodgson et al., "Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients," Circulation, vol. 105, no. 12, pp. 1412-1415, 2002.
2. F. Schiele, N. Meneveau, M. F. Seronde et al., "C-reactive protein improves risk prediction in patientswith acute coronary syndromes," European Heart Journal, vol. 31, no. 3, pp. 290-297, 2010.
3. W. K. Lagrand, H. W. M. Niessen, G. J. Wolbink et al., "Creactive protein colocalizes with complement in human hearts during acute myocardial infarction," Circulation, vol. 95, no. 1, pp. 97-103, 1997.
4. T. Takahashi, T. Anzai, H. Kaneko et al., "Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 299, no. 6, pp. H1795-H1804, 2010.
5. T. Takahashi, T. Anzai, T. Yoshikawa et al., "Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction-role of neurohormones and cytokines," International Journal of Cardiology, vol. 88,no. 2-3, pp. 257-265, 2003.
6. A. J. Nauta, B. Bottazzi, A. Mantovani et al., "Biochemical and functional characterization of the interaction between pentraxin 3 and C1q," European Journal of Immunology, vol. 33, no. 2, pp. 465-473, 2003.
7. L. Deban, R. C. Russo, M. Sironi et al., "Regulation of leukocyte recruitment by the long pentraxin PTX3," Nature Immunology, vol. 11, no. 4, pp. 328-334, 2010.
8. N. Maugeri, P. Rovere-Querini, M. Slavich et al., "Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction," Journal of Immunology, vol. 187, no. 2, pp. 970-979, 2011.
9. M. Salio, S. Chimenti, N. de Angelis et al., "Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction," Circulation, vol. 117, no. 8, pp. 1055-1064, 2008.
10. G. Peri,M. Introna, D. Corradi et al., "PTX3, a prototypical long pentraxin, is an early indicator of acutemyocardial infarction in humans," Circulation, vol. 102, no. 6, pp. 636-641, 2000.
11. M. Nebuloni, F. Pasqualini, P. Zerbi et al., "PTX3 expression in the heart tissues of patients with myocardial infarction and infectiousmyocarditis," Cardiovascular Pathology, vol. 20, no. 1, pp. e27-e35, 2011.
12. C. Garlanda, B. Bottazzi, A. Bastone, and A. Mantovani, "Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility," Annual Review of Immunology, vol. 23, pp. 337-366, 2005.
13. A. Basile, A. Sica, E. D'Aniello et al., "Characterization of the promoter for the human long pentraxin PTX3: role of NF-B in tumor necrosis factor-and interleukin-1 regulation," The Journal of Biological Chemistry, vol. 272, no. 13, pp. 8172-8178, 1997.
14. R. Latini, A. P. Maggioni, G. Peri et al., "Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction," Circulation, vol. 110, no. 16, pp. 2349-2354, 2004.
15. K. M. Eggers, P. W. Armstrong, R. M. Califf et al., "Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome," Clinical Biochemistry, vol. 46, no. 16-17, pp. 1655-1659, 2013.
16. K. A. Eagle, M. J. Lim, O. H. Dabbous et al., "A validated prediction model for all forms of acute coronary syndrome- estimating the risk of 6-month postdischarge death in an international registry," Journal of the American Medical Association, vol. 291, no. 22, pp. 2727-2733, 2004.
17. D. A. Morrow, E. M. Antman, A. Charlesworth et al., "TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation-an intravenous nPA for treatment of infarcting myocardium early II trial substudy," Circulation, vol. 102, no. 17, pp. 2031-2037, 2000.
18. C. Mueller, "Biomarkers and ST-elevation myocardial infarction," Heart, vol. 99, no. 16, 2013.
19. I. F. F. Benzie and J. J. Strain, "Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration," Methods in Enzymology: Oxidants and Antioxidants Part A, vol. 299, pp. 15-27, 1999.
20. G. A. Khoschsorur, B. M. Winklhofer-Roob, H. Rabl, T. Auer, Z. Peng, and R. J. Schaur, "Evaluation of a sensitive HPLCmethod for the determination of malondialdehyde, and application of themethod to different biological materials," Chromatographia, vol. 52, no. 3-4, pp. 181-184, 2000.
21. B. Vester and K. Rasmussen, "High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum," European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 29, no. 9, pp. 549-554, 1991.
22. W. J. Driskell, J. W. Neese, C. C. Bryant, and M. M. Bashor, "Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography," Journal of Chromatography, vol. 231, no. 2, pp. 439-444, 1982.
23. S. Kundu, Y. S. Aulchenko, C. M. Van Duijn, and A. C. J. W. Janssens, "PredictABEL: an R package for the assessment of risk prediction models," European Journal of Epidemiology, vol. 26, no. 4, pp. 261-264, 2011.
24. E. Barbati, C. Specchia,M. Villella et al., "nfluence of pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels," PLoSONE, vol. 7, no. 12, Article IDe53030, 2012.
25. H. F. Weisman, T. Bartow, M. K. Leppo et al., "Soluble human complement receptor type 1-in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis," Science, vol. 249, no. 4965, pp. 146-151, 1990.
26. P. Kunes, Z. Holubcova, M. Kolackova, and J. Krejsek, "Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response," Mediators of Inflammation, vol. 2012, Article ID 920517, 10 pages, 2012.
27. T. Anzai, T. Yoshikawa, H. Shiraki et al., "C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction," Circulation, vol. 96, no. 3, pp. 778-784, 1997.
28. B. M. Scirica, D. A. Morrow, C. P. Cannon et al., "Clinical application of C-reactive protein across the spectrum of acute coronary syndromes," Clinical Chemistry, vol. 53, no. 10, pp. 1800-1807, 2007.
29. L. K. Newby, M. S. Marber, C. Melloni et al., "Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevationmyocardial infarction: a randomised phase 2 trial," The Lancet, vol. 384, no. 9949, pp. 1187-1195, 2014.
30. C. Huber, J. R. Batchelor, D. Fuchs et al., "Immune responseassociated production of neopterin-release frommacrophages primarily under control of interferon-gamma," Journal of Experimental Medicine, vol. 160, no. 1, pp. 310-316, 1984.
31. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and M. Garcia-Gonzalez, "Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction," International Journal of Cardiology, vol. 111, no. 2, pp. 318-320, 2006.
32. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, P. Avanzas, I. Laynez-Cerdeña, and J. C. Kaski, "Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention," Atherosclerosis, vol. 211, no. 2, pp. 574-578, 2010.
33. S. Gilles, S. Zahler, U. Welsch, C. P. Sommerhoff, and B. F. Becker, "Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers," Cardiovascular Research, vol. 60, no. 3, pp. 608-616, 2003.
34. E. S. Kehmeier,W. Lepper, M. Kropp et al., "TNF-, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention," Clinical Research in Cardiology, vol. 101, no. 10, pp. 815-827, 2012.
35. J. S. Hochman, "Cardiogenic shock complicating acutemyocardial infarction: expanding the paradigm," Circulation, vol. 107, no. 24, pp. 2998-3002, 2003.
36. J. P. Monassier, "Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: basic considerations," Archives of Cardiovascular Diseases, vol. 101, no. 7-8, pp. 491-500, 2008.
37. R. A. Najar, S. M. H. Ghaderian, H. Vakili et al., "The role of p53, bax, bcl2, and 8-OHdG in human acute myocardial infarction," Central European Journal of Biology, vol. 5, no. 4, pp. 439-445, 2010.
38. H. Inafuku, Y. Kuniyoshi, S. Yamashiro et al., "Determination of oxidative stress and cardiac dysfunction after ischemia/reperfusion injury in isolated rat hearts," Annals of Thoracic and Cardiovascular Surgery, vol. 19, no. 3, pp. 186-194, 2013.
39. C. Lazzeri, S. Valente, M. Chiostri, A. Sori, P. Bernardo, and G. F. Gensini, "Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers. A single center experience," International Journal of Cardiology, vol. 138, no. 2, pp. 206-209, 2010.
40. A. L. Hill, D. A. Lowes, N. R. Webster, C. C. Sheth, N. A. R. Gow, and H. F. Galley, "Regulation of pentraxin-3 by antioxidants," British Journal of Anaesthesia, vol. 103, no. 6, pp. 833-839, 2009.
41. D. Simíc, J. Mimíc-Oka, M. Pljessa et al., "Time course erythrocyte antioxidant activity in patients treated by thrombolysis for acutemyocardial infarction," Japanese Heart Journal, vol. 44,no. 6, pp. 823-832, 2003.
42. M. D. Bagatini, C. C. Martins, V. Battisti et al., "Oxidative stress versus antioxidant defenses in patients with acute myocardial infarction," Heart and Vessels, vol. 26, no. 1, pp. 55-63, 2011.